Bio-Rad Laboratories, Inc. (BIO.B)

Bio-Rad Laboratories Statistics

Total Valuation

BIO.B has a market cap or net worth of $10.16 billion. The enterprise value is $9.92 billion.

Market Cap	10.16B
Enterprise Value	9.92B

Important Dates

The last earnings date was Wednesday, October 30, 2024, after market close.

Earnings Date	Oct 30, 2024
Ex-Dividend Date	n/a

Share Statistics

BIO.B has 28.00 million shares outstanding. The number of shares has decreased by -3.47% in one year.

Shares Outstanding	28.00M
Shares Change (YoY)	-3.47%
Shares Change (QoQ)	-1.44%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	19.44M

Valuation Ratios

PE Ratio	n/a
Forward PE	31.59
PS Ratio	n/a
Forward PS	3.63
PB Ratio	n/a
P/FCF Ratio	41.10
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.52, with an EV/FCF ratio of 40.16.

EV / Earnings	n/a
EV / Sales	3.85
EV / EBITDA	20.52
EV / EBIT	29.71
EV / FCF	40.16

Financial Position

The company has a current ratio of 6.14, with a Debt / Equity ratio of 0.19.

Current Ratio	6.14
Quick Ratio	4.21
Debt / Equity	0.19
Debt / EBITDA	2.52
Debt / FCF	5.62
Interest Coverage	6.80

Financial Efficiency

Return on equity (ROE) is -9.79% and return on invested capital (ROIC) is 2.23%.

Return on Equity (ROE)	-9.79%
Return on Assets (ROA)	1.85%
Return on Capital (ROIC)	2.23%
Revenue Per Employee	$321,321
Profits Per Employee	-$96,973
Employee Count	8,030
Asset Turnover	0.23
Inventory Turnover	1.48

Taxes

Income Tax	-226.50M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +22.66% in the last 52 weeks. The beta is 0.95, so BIO.B's price volatility has been similar to the market average.

Beta (5Y)	0.95
52-Week Price Change	+22.66%
50-Day Moving Average	330.48
200-Day Moving Average	313.18
Relative Strength Index (RSI)	99.59
Average Volume (20 Days)	26

Short Selling Information

The latest short interest is 2, so 0.00% of the outstanding shares have been sold short.

Short Interest	2
Short Previous Month	70
Short % of Shares Out	0.00%
Short % of Float	0.00%
Short Ratio (days to cover)	0.33

Income Statement

In the last 12 months, BIO.B had revenue of $2.58 billion and -$778.69 million in losses. Loss per share was -$27.41.

Revenue	2.58B
Gross Profit	1.41B
Operating Income	333.89M
Pretax Income	n/a
Net Income	-778.69M
EBITDA	483.49M
EBIT	333.89M
Loss Per Share	-$27.41

Balance Sheet

The company has $1.62 billion in cash and $1.39 billion in debt, giving a net cash position of $234.38 million or $8.37 per share.

Cash & Cash Equivalents	1.62B
Total Debt	1.39B
Net Cash	234.38M
Net Cash Per Share	$8.37
Equity (Book Value)	7.49B
Book Value Per Share	267.46
Working Capital	2.56B

Cash Flow

In the last 12 months, operating cash flow was $412.00 million and capital expenditures -$164.93 million, giving a free cash flow of $247.07 million.

Operating Cash Flow	412.00M
Capital Expenditures	-164.93M
Free Cash Flow	247.07M
FCF Per Share	$8.82

Margins

Gross margin is 54.54%, with operating and profit margins of 12.94% and -30.18%.

Gross Margin	54.54%
Operating Margin	12.94%
Pretax Margin	-38.96%
Profit Margin	-30.18%
EBITDA Margin	18.74%
EBIT Margin	12.94%
FCF Margin	n/a

Dividends & Yields

BIO.B does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.47%
Shareholder Yield	3.47%
Earnings Yield	-7.67%
FCF Yield	2.43%

Analyst Forecast

The average price target for BIO.B is $411.00, which is 22.74% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$411.00
Price Target Difference	22.74%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	3.35%
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.

Last Split Date	Mar 8, 2002
Split Type	Forward
Split Ratio	2:1

Scores

BIO.B has an Altman Z-Score of 3.43 and a Piotroski F-Score of 6.

Altman Z-Score	3.43
Piotroski F-Score	6